A carregar...

NPY(1)R-targeted peptide-mediated delivery of a dual PPARα/γ agonist to adipocytes enhances adipogenesis and prevents diabetes progression

OBJECTIVE: PPARα/γ dual agonists have been in clinical development for the treatment of metabolic diseases including type 2 diabetes and dyslipidemia. However, severe adverse side effects led to complications in clinical trials. As most of the beneficial effects rely on the compound activity in adip...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Mol Metab
Main Authors: Wittrisch, Stefanie, Klöting, Nora, Mörl, Karin, Chakaroun, Rima, Blüher, Matthias, Beck-Sickinger, Annette G.
Formato: Artigo
Idioma:Inglês
Publicado em: Elsevier 2019
Assuntos:
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6931124/
https://ncbi.nlm.nih.gov/pubmed/31918918
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.molmet.2019.11.009
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!